TheBitCast

OncLive® On Air

Autor: OncLive® On Air

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Odcinki

  1. Thorough Treatment Adherence and Selection Anchor Proper TKI Utilization in CML – OncLive® On Air
  2. How Allergists Fit Into the Systemic Mastocytosis Management Equation – OncLive® On Air
  3. Board Review 2026: Top Hematology/Oncology Topics to Know – OncLive® On Air
  4. Beyond PD-L1: Refining First-Line Treatment Decisions in Metastatic NSCLC – OncLive® On Air
  5. Order Both IHC and NGS: Defining MET Alterations and Positioning Telisotuzumab Vedotin in Non–Small Cell Lung Cancer – OncLive® On Air
  6. Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape – OncLive® On Air
  7. FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer – OncLive® On Air
  8. Biology-Driven Care and AI Tools Steer the Future of Breast Oncology – OncLive® On Air
  9. Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma – OncLive® On Air
  10. Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers – OncLive® On Air
  11. The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer – OncLive® On Air
  12. Navigating Patient-Centric Treatment Administration Strategies in Myeloma – OncLive® On Air
  13. Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer – OncLive® On Air
  14. FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia – OncLive® On Air
  15. FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma – OncLive® On Air
  16. Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma – OncLive® On Air
  17. Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma – OncLive® On Air
  18. Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape – OncLive® On Air
  19. Start Earlier and Find Your Community: Navigating the Fellowship-to-Faculty Transition Through Mentorship and Specialty-Focused Meetings – OncLive® On Air
  20. OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma – OncLive® On Air
  21. Dissecting Diagnostic and Management Factors in Systemic Mastocytosis – OncLive® On Air
  22. Unpacking Data and Upcoming Developments for Olverembatinib in CML – OncLive® On Air
  23. Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice – OncLive® On Air
  24. Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer – OncLive® On Air
  25. Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management – OncLive® On Air
  26. Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer – OncLive® On Air
  27. Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC – OncLive® On Air
  28. INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management – OncLive® On Air
  29. Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond – OncLive® On Air
  30. Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care – OncLive® On Air